Form 4 for PCSA Processa Pharmaceuticals, Inc.
Accepted 2022-04-04 00:00:00 ET · period of report 2021-11-01 · accession 0001567619-22-007993 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-04-04 | 2022-03-31 | PCSA | Floyd Robert Michael | COO | G - Gift | $0.00 | -7,000 | 70.9K | -9% | $0 |
| DM | 2022-04-04 | 2021-11-01+ | PCSA | Floyd Robert Michael | COO | A - Grant | $0.00 | +15.0K | 27.1K | +124% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-31 | G | D | 7,000 | $0.00 | 70,930 | D | — | — | (F1) Shares previously reported as indirectly held by Elion Oncology were transferred to the reporting person's direct holdings in an transaction exempt from Section 16 reporting. |
| 2 | Derivative | Restricted Stock Units | 2022-03-31 | A | A | 10,715 | $0.00 | 37,781 | D | $0.00 · — to — | 10,715 Common Stock | (F2) Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. |
| 3 | Derivative | Restricted Stock Units | 2021-11-01 | A | A | 4,286 | $0.00 | 27,066 | D | $0.00 · — to — | 4,286 Common Stock | (F2) Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. |